Topical dexamethasoneγ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

Autor:	Masaki Tanito, Akihiro Ohira, Gauti Jóhannesson, Gudrun Marta Asgrimsdottir, Sigrun H. Lund, Einar Stefánsson, Thorsteinn Loftsson, Katsunori Hara
Rok vydání:	2015
Předmět:	Male medicine.medical_specialty Visual acuity Triamcinolone acetonide Tenon Capsule Administration Topical Visual Acuity Triamcinolone Acetonide Dexamethasone Macular Edema Retina Ophthalmology medicine Humans Prospective Studies Glucocorticoids Macular edema Aged chemistry.chemical_classification Diabetic Retinopathy Cyclodextrin business.industry General Medicine Diabetic retinopathy Middle Aged medicine.disease medicine.anatomical_structure chemistry Diabetic macular oedema Nanoparticles Female Injections Intraocular Ophthalmic Solutions medicine.symptom business Tomography Optical Coherence gamma-Cyclodextrins medicine.drug
Zdroj:	Acta Ophthalmologica. 93:610-615
ISSN:	1755-375X
Popis:	To compare in a randomized, controlled trial topical 1.5% dexamethasone γ-cyclodextrin nanoparticle eye drops (DexNP) with posterior subtenon injection of triamcinolone acetonide in diabetic macular oedema (DME).In this prospective, randomized, controlled trial, 22 eyes of 22 consecutive patients with DME were randomized to (i) topical treatment with DexNP ×3/day (4 weeks), ×2/day (4 weeks) and ×1/day (4 weeks) or (ii) one posterior subtenon injection of 20 mg triamcinolone acetonide. Study visits were at baseline and 4, 8, 12 and 16 weeks.The logMAR (Snellen) visual acuity (mean ± SD) improved significantly with DexNP from 0.41 ± 0.3 (Snellen 0.39) to 0.32 ± 0.25 (0.48) and 0.30 ± 0.26 (0.50) at 4 and 8 weeks, respectively. One-third of the DexNP group improved more than 0.3 logMAR units. For triamcinolone, logMAR changed significantly from 0.42 ± 0.28 (0.38) at baseline to 0.32 ± 0.29 (0.48) at 4w and 0.33 ± 0.37 (0.47) at 12w. The central macular thickness (CMT) decreased significantly with DexNP from 483 ± 141 μm to 384 ± 142 μm at 4w and 342 ± 114 μm at 8w. For triamcinolone, CMT decreased significantly at all time-points: 494 ± 94 μm, 388 ± 120, 388 ± 145, 390 ± 136 and 411 ± 104 μm at 0, 4, 8, 12 and 16 weeks, respectively. There was a modest increase in intraocular pressure (IOP) at all time-points with DexNP while no increase was seen with triamcinolone. Serum cortisol was affected by both treatments.Topical DexNP significantly improve visual acuity and decrease macular thickness in patients with DME. The effect is similar to that from subtenon triamcinolone. A modest increase in IOP was seen with the nanoparticle eye drops, but IOP normalized after the discontinuation of treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155bb9fc41533872cac0a67525a4f898 https://doi.org/10.1111/aos.12803 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.